MCID: GLM025
MIFTS: 15

Glioma Susceptibility 2

Categories: Genetic diseases, Neuronal diseases

Aliases & Classifications for Glioma Susceptibility 2

MalaCards integrated aliases for Glioma Susceptibility 2:

Name: Glioma Susceptibility 2 57 29 13 6
Glm2 57 75
Glioma, Susceptibility, Type 2 40
Glioma 2 75

Classifications:



External Ids:

OMIM 57 613028
MedGen 42 C2751642
MeSH 44 D005910

Summaries for Glioma Susceptibility 2

UniProtKB/Swiss-Prot : 75 Glioma 2: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.

MalaCards based summary : Glioma Susceptibility 2, also known as glm2, is related to meningioma, familial. An important gene associated with Glioma Susceptibility 2 is PTEN (Phosphatase And Tensin Homolog). The drugs Antibodies and Antibodies, Monoclonal have been mentioned in the context of this disorder.

Description from OMIM: 613028

Related Diseases for Glioma Susceptibility 2

Diseases in the Glioma Susceptibility 1 family:

Glioma Susceptibility 4 Glioma Susceptibility 2
Glioma Susceptibility 3 Glioma Susceptibility 5
Glioma Susceptibility 6 Glioma Susceptibility 7
Glioma Susceptibility 8 Glioma Susceptibility 9

Diseases related to Glioma Susceptibility 2 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 meningioma, familial 11.0

Symptoms & Phenotypes for Glioma Susceptibility 2

Clinical features from OMIM:

613028

Drugs & Therapeutics for Glioma Susceptibility 2

Drugs for Glioma Susceptibility 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 3
2 Antibodies, Monoclonal Phase 3
3 Antirheumatic Agents Phase 3
4 Immunoglobulins Phase 3

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2) Completed NCT00975130 Phase 3

Search NIH Clinical Center for Glioma Susceptibility 2

Genetic Tests for Glioma Susceptibility 2

Genetic tests related to Glioma Susceptibility 2:

# Genetic test Affiliating Genes
1 Glioma Susceptibility 2 29 PTEN

Anatomical Context for Glioma Susceptibility 2

Publications for Glioma Susceptibility 2

Variations for Glioma Susceptibility 2

UniProtKB/Swiss-Prot genetic disease variations for Glioma Susceptibility 2:

75
# Symbol AA change Variation ID SNP ID
1 PTEN p.Arg234Gln VAR_018106 rs121909235

Expression for Glioma Susceptibility 2

Search GEO for disease gene expression data for Glioma Susceptibility 2.

Pathways for Glioma Susceptibility 2

GO Terms for Glioma Susceptibility 2

Sources for Glioma Susceptibility 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....